Polish hospital records reveal Real-World impact of Immuno-Chemo combo on lung cancer
NCT ID NCT07526961
First seen Apr 19, 2026 · Last updated Apr 29, 2026 · Updated 2 times
Summary
This study looked back at the medical records of 240 adults in Poland with advanced non-small cell lung cancer who received a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment. The goal was to see how well this treatment works in everyday hospital practice, not just in controlled trials. Researchers measured things like tumor shrinkage, how long patients lived without the cancer getting worse, and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Wielkopolska Center of Pulmonology and Thoracic Surgery of Eugenia and Janusz Zeyland
Poznan, Poland
Conditions
Explore the condition pages connected to this study.